secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001493152-23-012483
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa Biosciences and Cleveland Clinic report positive Phase 1 data for breast cancer vaccine
--------------------------------------------------------------------------------

- Phase 1 trial of triple-negative breast cancer vaccine showed antigen-specific T cell responses at all dose levels.
- Trial funded by U.S. Department of Defense; Anixa is exclusive worldwide licensee from Cleveland Clinic.
- Participants were tumor-free women with history of TNBC, curatively treated, at high risk of recurrence.
- Phase 1a study evaluates safety, MTD, and immune response; not designed to measure recurrence prevention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315223012483/0001493152-23-012483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315223012483/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer